Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.

Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.

Item
http://www.wikidata.org/entity/Q36385912
Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders.Activation of peroxisome proliferator-activated receptor α induces lysosomal biogenesis in brain cells: implications for lysosomal storage disordersProgress in the Development of Small Molecule Therapeutics for the Treatment of Neuronal Ceroid Lipofuscinoses (NCLs).Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Upregulates Ciliary Neurotrophic Factor in Astrocytes and Oligodendrocytes.PPARα in lysosomal biogenesis: A perspective.Up-regulation of ciliary neurotrophic factor in astrocytes by aspirin: implications for remyelination in multiple sclerosis.Implications of a peroxisome proliferator-activated receptor alpha (PPARα) ligand clofibrate in breast cancerCastration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthaseHuman iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapyLysosomal storage diseases--the horizon expands.Master Autophagy Regulator Transcription Factor EB Regulates Cigarette Smoke-Induced Autophagy Impairment and Chronic Obstructive Pulmonary Disease-Emphysema Pathogenesis.Bexarotene, a Selective RXRα Agonist, Reverses Hypotension Associated with Inflammation and Tissue Injury in a Rat Model of Septic Shock.Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.Comparative assessment of strategies to identify similar ligand-binding pockets in proteins.
P2860

Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.

Item
http://www.wikidata.org/entity/Q36385912
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@ast
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@en
type
label
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@ast
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@en
prefLabel
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@ast
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Gemfibrozil and fenofibrate, F ...... antile Batten disease therapy.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932